NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
63 trialsNCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT06317298 2024-03-19
Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
Peking University First Hospital
Phase NA Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT00830895 2022-11-09
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Seoul National University Hospital
Phase 2 Completed
NCT03163667 2022-09-15
ENTRATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT01034631 2022-07-11
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT01399918 2022-02-01
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05124431 2021-11-18
ALTER-UC-001
Fudan University
Phase 2 Unknown
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01152801 2020-12-21
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
Novartis
Phase 1 Completed
NCT01482156 2020-12-21
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT01239342 2019-10-10
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01206764 2019-06-24
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Novartis
Phase 4 Completed
NCT01198158 2019-03-06
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01136733 2019-02-27
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Eisai Inc.
Phase 1/2 Completed
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00529802 2018-04-25
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
University of Chicago
Phase 2 Completed
NCT01107509 2018-04-04
Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
St. Joseph's Healthcare Hamilton
Phase NA Completed
NCT02338570 2018-02-05
ORCHIDEE
Mario Negri Institute for Pharmacological Research
Phase 4 Terminated
NCT01266837 2017-11-14
MARC-2
iOMEDICO AG
Phase 4 Completed
NCT00331409 2017-10-26
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01514448 2017-07-19
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Novartis
Phase 4 Completed
NCT01462214 2017-05-10
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00688753 2016-09-02
MACS0460
Novartis
Phase 2 Completed
NCT01442090 2016-08-10
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
Genentech, Inc.
Phase 2 Completed
NCT01491672 2016-06-06
RECORD-4
Novartis
Phase 2 Completed
NCT00831480 2016-03-21
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Baylor College of Medicine
Phase 2 Terminated
NCT00446368 2016-03-17
RAD001
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed